SRH Advisors’s Merck MRK Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $28.5K | Sell |
222
-2,045
| -90% | -$239K | 0.01% | 170 |
|
|
2026
Q1 | $273K | Hold |
2,267
| – | – | 0.08% | 44 |
|
|
2025
Q4 | $239K | Hold |
2,267
| – | – | 0.07% | 55 |
|
|
2025
Q3 | $190K | Hold |
2,267
| – | – | 0.06% | 62 |
|
|
2025
Q2 | $179K | Hold |
2,267
| – | – | 0.05% | 61 |
|
|
2025
Q1 | $203K | Hold |
2,267
| – | – | 0.06% | 55 |
|
|
2024
Q4 | $226K | Hold |
2,267
| – | – | 0.07% | 51 |
|
|
2024
Q3 | $257K | Hold |
2,267
| – | – | 0.08% | 50 |
|
|
2024
Q2 | $281K | Hold |
2,267
| – | – | 0.09% | 47 |
|
|
2024
Q1 | $299K | Hold |
2,267
| – | – | 0.09% | 48 |
|
|
2023
Q4 | $247K | Hold |
2,267
| – | – | 0.09% | 48 |
|
|
2023
Q3 | $233K | Hold |
2,267
| – | – | 0.11% | 50 |
|
|
2023
Q2 | $241K | Hold |
2,267
| – | – | 0.13% | 52 |
|
|
2023
Q1 | $241K | Hold |
2,267
| – | – | 0.13% | 52 |
|
|
2022
Q4 | $252K | Hold |
2,267
| – | – | 0.14% | 52 |
|
|
2022
Q3 | $195K | Hold |
2,267
| – | – | 0.25% | 56 |
|
|
2022
Q2 | $207K | Hold |
2,267
| – | – | 0.26% | 54 |
|
|
2022
Q1 | $186K | Hold |
2,267
| – | – | 0.21% | 64 |
|
|
2021
Q4 | $174K | Hold |
2,267
| – | – | 0.2% | 65 |
|
|
2021
Q3 | $170K | Hold |
2,267
| – | – | 0.21% | 64 |
|
|
2021
Q2 | $176K | Sell |
2,267
-109
| -5% | -$8.11K | 0.22% | 61 |
|
|
2021
Q1 | $175K | Hold |
2,376
| – | – | 0.25% | 55 |
|
|
2020
Q4 | $185K | Hold |
2,376
| – | – | 0.31% | 49 |
|
|
2020
Q3 | $188K | Hold |
2,376
| – | – | 0.36% | 45 |
|
|
2020
Q2 | $175K | Hold |
2,376
| – | – | 0.44% | 42 |
|
|
2020
Q1 | $174K | Hold |
2,376
| – | – | 0.48% | 42 |
|
|
2019
Q4 | $206K | Hold |
2,376
| – | – | 0.66% | 35 |
|
|
2019
Q3 | $191K | Hold |
2,376
| – | – | 0.64% | 38 |
|
|
2019
Q2 | $190K | Sell |
2,376
-92
| -4% | -$7.04K | 0.65% | 39 |
|
|
2019
Q1 | $196K | Hold |
2,468
| – | – | 0.7% | 37 |
|
|
2018
Q4 | $180K | Hold |
2,468
| – | – | 0.69% | 34 |
|
|
2018
Q3 | $167K | Buy |
2,468
+60
| +2% | +$3.82K | 0.57% | 43 |
|
|
2018
Q2 | $139K | Buy |
2,408
+92
| +4% | +$5.19K | 0.52% | 45 |
|
|
2018
Q1 | $120K | Hold |
2,316
| – | – | 0.48% | 46 |
|
|
2017
Q4 | $124K | Hold |
2,316
| – | – | 0.49% | 45 |
|
|
2017
Q3 | $142K | Hold |
2,316
| – | – | 0.6% | 42 |
|
|
2017
Q2 | $142K | Hold |
2,316
| – | – | 0.68% | 38 |
|
|
2017
Q1 | $140K | Hold |
2,316
| – | – | 0.65% | 36 |
|
|
2016
Q4 | $130K | Hold |
2,316
| – | – | 0.65% | 36 |
|
|
2016
Q3 | $138K | Hold |
2,316
| – | – | 0.72% | 36 |
|
|
2016
Q2 | $127K | Sell |
2,316
-80
| -3% | -$4.26K | 0.68% | 37 |
|
|
2016
Q1 | $121K | Hold |
2,396
| – | – | 0.67% | 37 |
|
|
2015
Q4 | $121K | Hold |
2,396
| – | – | 0.71% | 37 |
|
|
2015
Q3 | $113K | Hold |
2,396
| – | – | 0.66% | 38 |
|
|
2015
Q2 | $130K | Hold |
2,396
| – | – | 0.82% | 34 |
|
|
2015
Q1 | $131K | Hold |
2,396
| – | – | 0.87% | 32 |
|
|
2014
Q4 | $130K | Hold |
2,396
| – | – | 0.89% | 29 |
|
|
2014
Q3 | $136K | Hold |
2,396
| – | – | 1.05% | 23 |
|
|
2014
Q2 | $132K | Hold |
2,396
| – | – | 1.04% | 23 |
|
|
2014
Q1 | $130K | Buy |
2,396
+315
| +15% | +$16.3K | 1.04% | 23 |
|
|
2013
Q4 | $99K | Buy |
+2,081
| New | +$95.1K | 0.97% | 25 |
|
Other funds holding MRK
ECSS
ATO
SRH Advisors's MRK Position: Q2 2026 in Review
SRH Advisors reduced its Merck (MRK) stake by 90% in Q2 2026, selling an estimated $239K and leaving 222 shares worth $28.5K. The position accounts for 0.01% of the portfolio, ranked #170.
SRH Advisors first reported a position in MRK in Q4 2013 and has held it in 51 quarters since. The position peaked at $299K in Q1 2024. 1,659 funds tracked by Wall St. Rank hold MRK as of Q2 2026.
- SRH Advisors held 222 shares of Merck worth $28.5K as of Q2 2026.
- SRH Advisors sold 2,045 Merck shares in Q2 2026, an estimated $239K.
- Merck made up 0.01% of SRH Advisors's portfolio in Q2 2026, its #170 holding.
- SRH Advisors first reported a position in Merck in Q4 2013 and has held it in 51 quarters since.
- SRH Advisors's Merck position peaked at $299K in Q1 2024.
- 1,659 funds tracked by Wall St. Rank held Merck as of Q2 2026.
Based on SRH Advisors's 13F filing for Q2 2026, filed 24 Jul 2026.